Karachaliou N - Search Results

1

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.

Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, Ojo NC, Caldwell K, Abhyankar J, Boucher T, Hart MG, Makarov V, Montpreville VT, Mercier O, Chan TA, Scagliotti G, Bironzo P, Novello S, Karachaliou N, Rosell R, Anderson I, Gabrail N, Hrom J, Limvarapuss C, Choquette K, Spira A, Rousseau R, Voong C, Rizvi NA, Fadel E, Frattini M, Jooss K, Skoberne M, Francis J, Yelensky R. Bulik-Sullivan B, et al. Among authors: karachaliou n. Nat Biotechnol. 2018 Dec 17. doi: 10.1038/nbt.4313. Online ahead of print. Nat Biotechnol. 2018. PMID: 30556813

2

KRAS mutations in lung cancer.

Karachaliou N, Mayo C, Costa C, Magrí I, Gimenez-Capitan A, Molina-Vila MA, Rosell R. Karachaliou N, et al. Clin Lung Cancer. 2013 May;14(3):205-14. doi: 10.1016/j.cllc.2012.09.007. Epub 2012 Nov 1. Clin Lung Cancer. 2013. PMID: 23122493 Review.

3

Optimal detection of ALK rearranged lung adenocarcinomas.

Karachaliou N, Rosell R. Karachaliou N, et al. J Thorac Oncol. 2013 Mar;8(3):255-6. doi: 10.1097/JTO.0b013e318282ddc3. J Thorac Oncol. 2013. PMID: 23407554 Free article. No abstract available.

4

Small-cell lung cancer: where are we now and what can we expect for the future?

Karachaliou N, Rosell R. Karachaliou N, et al. Future Oncol. 2013 Aug;9(8):1065-8. doi: 10.2217/fon.13.85. Future Oncol. 2013. PMID: 23902237 No abstract available.

5

Lung cancer: Maintenance therapy and precision medicine in NSCLC.

Rosell R, Karachaliou N. Rosell R, et al. Among authors: karachaliou n. Nat Rev Clin Oncol. 2013 Oct;10(10):549-50. doi: 10.1038/nrclinonc.2013.152. Epub 2013 Aug 20. Nat Rev Clin Oncol. 2013. PMID: 23959270 No abstract available.

6

Genetics and biomarkers in personalisation of lung cancer treatment.

Rosell R, Bivona TG, Karachaliou N. Rosell R, et al. Among authors: karachaliou n. Lancet. 2013 Aug 24;382(9893):720-31. doi: 10.1016/S0140-6736(13)61715-8. Lancet. 2013. PMID: 23972815 Review.

7

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.

Karachaliou N, Rosell R, Morales-Espinosa D, Viteri S. Karachaliou N, et al. Expert Rev Anticancer Ther. 2014 Jul;14(7):807-15. doi: 10.1586/14737140.2014.896210. Epub 2014 Mar 10. Expert Rev Anticancer Ther. 2014. PMID: 24611674 Review.

8

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.

Karachaliou N, Rosell R. Karachaliou N, et al. Cancer Biol Med. 2014 Sep;11(3):173-81. doi: 10.7497/j.issn.2095-3941.2014.03.003. Cancer Biol Med. 2014. PMID: 25364578 Free PMC article. Review.

9

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.

Rosell R, Karachaliou N, Wolf J, Ou SH. Rosell R, et al. Among authors: karachaliou n. Lancet Respir Med. 2014 Dec;2(12):966-8. doi: 10.1016/S2213-2600(14)70259-0. Epub 2014 Nov 19. Lancet Respir Med. 2014. PMID: 25466349 No abstract available.

10

Lung cancer in 2014: optimizing lung cancer treatment approaches.

Rosell R, Karachaliou N. Rosell R, et al. Among authors: karachaliou n. Nat Rev Clin Oncol. 2015 Feb;12(2):75-6. doi: 10.1038/nrclinonc.2014.225. Epub 2014 Dec 23. Nat Rev Clin Oncol. 2015. PMID: 25533943 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

191 results

Search Page